Paracentesis in Patients with Elevated INR

Key Evidence Against Routine INR Correction

The American Gastroenterological Association (AGA) explicitly recommends against routine use of fresh frozen plasma (FFP) or platelets for bleeding prophylaxis in patients with stable cirrhosis undergoing paracentesis, as the bleeding risk remains extremely low (<1.5%) even with significant coagulopathy 1, 2
The European Association for the Study of the Liver (EASL) guidelines state there are no data to support the use of FFP or pooled platelets before paracentesis, even with severe coagulopathy (prothrombin activity <40%) and/or thrombocytopenia (<40,000/μL) 3
Multiple guidelines emphasize that paracentesis does not routinely require coagulation assessment before performance, with a large retrospective study of 3,116 paracenteses performed without prophylactic correction showing only 6 bleeding events (0.19%) 5, 6, 7

A study of 1,100 paracenteses found zero bleeding events in procedures performed with platelets <50×10⁹/L and INR >1.5, highlighting the low risk of bleeding in these patients 4, 8
Even in patients with severe coagulopathy, only 2 minor cutaneous bleedings occurred out of 142 paracenteses in patients with INR >1.5 and platelets <50,000/μL, further supporting the low bleeding risk 3

Patients with stable cirrhosis have a "rebalanced" hemostatic system where both pro-coagulant and anti-coagulant factors are proportionally reduced, making INR a poor predictor of bleeding risk 5, 6, 7
The INR was designed to monitor warfarin therapy, not to assess bleeding risk in liver disease, and correlates poorly with actual bleeding risk during procedures 9, 1

Acute kidney injury is the only independent risk factor consistently associated with post-paracentesis bleeding and should prompt heightened awareness, with patients on therapeutic anticoagulation (warfarin, heparin, DOACs) requiring separate consideration and may have increased bleeding risk 9, 2, 4
Patients with acute-on-chronic liver failure or decompensated liver disease with progressive consumptive coagulopathy may represent exceptions where management differs, and disseminated intravascular coagulation is a contraindication to paracentesis 9, 4, 3

Check baseline INR and platelet count for documentation purposes, not to guide prophylactic transfusion decisions, and assess for acute kidney injury, which is the primary modifiable risk factor for bleeding 5, 4, 2
Evaluate for signs of decompensation or acute-on-chronic liver failure rather than focusing on coagulation parameters, and use real-time ultrasound guidance, which has been associated with near-zero hemorrhage risk (0.19%) without coagulation correction 1, 2, 3

Do not routinely transfuse FFP or platelets based solely on elevated INR or low platelet counts, as this practice increases costs, delays procedures, and may worsen outcomes, and do not assume that correcting INR to "normal" ranges will reduce bleeding risk - no evidence supports commonly used thresholds for INR correction 1, 3, 2, 9
Do not withhold necessary paracentesis due to coagulopathy concerns in stable cirrhosis patients - the procedure itself carries minimal risk, and do not overlook acute kidney injury as the primary modifiable bleeding risk factor 3, 5, 7, 2, 4, 8